Skip to main content

Qiming Venture Partners VI, L.P.'s Form 4 filing

Alamar Biosciences, Inc.ALMR · filed Nov 5, 2026

Accession no.
0001231919-26-001540
Filed
Nov 5, 2026, 4:10 PM ET
Trade date
Nov 3, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market sales total $3.33M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Qiming Venture Partners VI, L.P.CIK 000173327810% Owner
Qiming Managing Directors Fund VI, L.P.CIK 000173328210% Owner
Qiming Venture Partners VIII-HC, L.P.CIK 000191002510% Owner
Qiming Corporate GP VI, Ltd.CIK 000205912710% Owner
Qiming Venture Partners VIII Investments, LLCCIK 000212961810% Owner
Qiming GP VIII-HC, LLCCIK 000212967110% Owner
Qiming GP VIII, LLCCIK 000212974010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 3, 2026Common StockSSaleDisposed−1,946$29.89F1−$58,165.94158,967Indirect
Nov 3, 2026Common StockSSaleDisposed−72,301$29.89F1−$2,161,076.895,907,803Indirect
Nov 3, 2026Common StockSSaleDisposed−16,870$29.89F1−$504,244.31,378,474Indirect
Nov 3, 2026Common StockSSaleDisposed−20,196$29.89F1−$603,658.441,650,354Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.40 to $30.22, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote

Referenced by the price of 4 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)